UAB investigators have won a prestigious White House BRAIN Initiative grant to study the potential benefits of new technology coupled with newly discovered biomarkers in deep brain stimulation for Parkinson’s disease.
UAB and partners launch the PREVeNT study, aimed at preventing the onset of seizures in children with tuberous sclerosis.
A UAB study sheds light on and suggests a target for treatment of a variant of Guillain-Barré syndrome.
An NIH grant will help support personalized medicine and patient-oriented research at UAB.
The mechanism of widespread reorganization of DNA methylation may be a therapeutic target to prevent or reverse dyskinesia.
Researchers have found that an interaction between a mutant gene and alpha synuclein in neurons leads to hallmark pathologies seen in Parkinson’s disease, findings that may lead to new mechanisms and targets for neuroprotection.
The biomarker, the protein kinase LRRK2, is a promising candidate for future exploration.
Two members of the School of Medicine faculty have been selected as fellows for the Hedwig van Ameringen Executive Leadership in Academic Medicine® for 2016-2017.
Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.
Preliminary results from UAB’s CBD oil studies show benefit in seizure control in some patients.